Capricor Therapeutics, Inc. is a Delaware-based biotechnology company focused on developing cell and exosome-based therapeutics for Duchenne muscular dystrophy (DMD) and other diseases with significant unmet medical need. Its lead product candidate, Deramiocel, is a cardiosphere-derived cell (CDC) therapy with a BLA under FDA review (PDUFA date: August 22, 2026). The company also advances its exosome platform (StealthX) for infectious diseases, monogenic diseases, and other indications through collaborations with NIH, DoD, Johns Hopkins, and others.
Q2 FY2026 — expected 2026-08-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-17 | 2025-12-31 | 0001104659-26-029580 | EDGAR | 90K words |
| 2025-03-26 | 2024-12-31 | 0001558370-25-003707 | EDGAR | — |
| 2024-03-11 | 2023-12-31 | 0001558370-24-002861 | EDGAR | — |
| 2023-03-17 | 2022-12-31 | 0001558370-23-004124 | EDGAR | — |
| 2022-03-11 | 2021-12-31 | 0001558370-22-003341 | EDGAR | — |
| 2021-03-15 | 2020-12-31 | 0001104659-21-036410 | EDGAR | — |
| 2020-03-27 | 2019-12-31 | 0001104659-20-039272 | EDGAR | — |
| 2019-03-29 | 2018-12-31 | 0001144204-19-016787 | EDGAR | — |
| 2018-03-22 | 2017-12-31 | 0001144204-18-016468 | EDGAR | — |
| 2017-03-16 | 2016-12-31 | 0001144204-17-014866 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-10 | 2025-09-30 | 0001104659-25-109298 | EDGAR | 32K words |
| 2025-08-11 | 2025-06-30 | 0001558370-25-011084 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0001558370-25-007770 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001558370-24-015730 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001558370-24-011638 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0001558370-24-008072 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001558370-23-019065 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0001558370-23-013763 | EDGAR | — |
| 2023-05-12 | 2023-03-31 | 0001558370-23-009521 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001558370-22-017470 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0001558370-22-013383 | EDGAR | — |
| 2022-05-11 | 2022-03-31 | 0001558370-22-008347 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-12 | 0001104659-26-027037 | EDGAR | 3K words |
| 2026-03-10 | 0001104659-26-025657 | EDGAR | — |
| 2025-12-05 | 0001104659-25-118934 | EDGAR | — |
| 2025-12-03 | 0001104659-25-117981 | EDGAR | — |
| 2025-12-03 | 0001104659-25-117947 | EDGAR | — |
| 2025-11-10 | 0001104659-25-109119 | EDGAR | — |
| 2025-08-11 | 0001558370-25-011047 | EDGAR | — |
| 2025-07-11 | 0001558370-25-009186 | EDGAR | — |
| 2025-05-27 | 0001558370-25-008145 | EDGAR | — |
| 2025-05-13 | 0001558370-25-007574 | EDGAR | — |
363 total filings indexed. 331 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001133869 |
| Ticker | CAPR |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.capricor.com |
| Listed | 2002-06-20 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report